These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14665873)

  • 1. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
    Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Kishi T; Nakamura T; Loening SA; Diamandis EP
    J Urol; 2004 Jan; 171(1):187-91. PubMed ID: 14665873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
    Yousef GM; Stephan C; Scorilas A; Ellatif MA; Jung K; Kristiansen G; Jung M; Polymeris ME; Diamandis EP
    Prostate; 2003 Sep; 56(4):287-92. PubMed ID: 12858357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
    Chen Z; Fan Z; McNeal JE; Nolley R; Caldwell MC; Mahadevappa M; Zhang Z; Warrington JA; Stamey TA
    J Urol; 2003 Apr; 169(4):1316-9. PubMed ID: 12629351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
    Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
    Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
    Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
    J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
    Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Bharaj BS; Nakamura T; Loening SA; Diamandis E
    J Urol; 2003 Jan; 169(1):361-4. PubMed ID: 12478190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.
    Sidiropoulos M; Chang A; Jung K; Diamandis EP
    Br J Cancer; 2001 Aug; 85(3):393-7. PubMed ID: 11487271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
    Kishi H; Igawa M; Kikuno N; Yoshino T; Urakami S; Shiina H
    J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma.
    Väre P; Loikkanen I; Hirvikoski P; Vaarala MH; Soini Y
    Oncol Rep; 2008 Jan; 19(1):25-31. PubMed ID: 18097572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling reveals hepsin overexpression in prostate cancer.
    Magee JA; Araki T; Patil S; Ehrig T; True L; Humphrey PA; Catalona WJ; Watson MA; Milbrandt J
    Cancer Res; 2001 Aug; 61(15):5692-6. PubMed ID: 11479199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
    Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
    J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of ezrin in prostatic intraepithelial neoplasia.
    Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
    Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
    J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of BMP7 in human colorectal cancer.
    Motoyama K; Tanaka F; Kosaka Y; Mimori K; Uetake H; Inoue H; Sugihara K; Mori M
    Ann Surg Oncol; 2008 May; 15(5):1530-7. PubMed ID: 18259822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
    Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
    Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
    Halvorsen OJ; Oyan AM; Bø TH; Olsen S; Rostad K; Haukaas SA; Bakke AM; Marzolf B; Dimitrov K; Stordrange L; Lin B; Jonassen I; Hood L; Akslen LA; Kalland KH
    Int J Oncol; 2005 Feb; 26(2):329-36. PubMed ID: 15645116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
    Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
    J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.